Inserm UMR1018, Paris South, Paris Saclay university, centre of research in epidemiology and population health (CESP), 94800 Villejuif, France.
Inserm UMR1153, Paris Descartes University, AP-HP, centre of research in epidemiology and statistics, Sorbonne Paris Cité (CRESS), 75004 Paris, France.
Diabetes Metab. 2019 Sep;45(4):322-329. doi: 10.1016/j.diabet.2018.08.012. Epub 2018 Sep 19.
Digital medicine, digital research and artificial intelligence (AI) have the power to transform the field of diabetes with continuous and no-burden remote monitoring of patients' symptoms, physiological data, behaviours, and social and environmental contexts through the use of wearables, sensors and smartphone technologies. Moreover, data generated online and by digital technologies - which the authors suggest be grouped under the term 'digitosome' - constitute, through the quantity and variety of information they represent, a powerful potential for identifying new digital markers and patterns of risk that, ultimately, when combined with clinical data, can improve diabetes management and quality of life, and also prevent diabetes-related complications. Moving from a world in which patients are characterized by only a few recent measurements of fasting glucose levels and glycated haemoglobin to a world where patients, healthcare professionals and research scientists can consider various key parameters at thousands of time points simultaneously will profoundly change the way diabetes is prevented, managed and characterized in patients living with diabetes, as well as how it is scientifically researched. Indeed, the present review looks at how the digitization of diabetes can impact all fields of diabetes - its prevention, management, technology and research - and how it can complement, but not replace, what is usually done in traditional clinical settings. Such a profound shift is a genuine game changer that should be embraced by all, as it can provide solid research results transferable to patients, improve general health literacy, and provide tools to facilitate the everyday decision-making process by both healthcare professionals and patients living with diabetes.
数字医学、数字研究和人工智能 (AI) 通过使用可穿戴设备、传感器和智能手机技术,能够对患者的症状、生理数据、行为以及社会和环境背景进行持续、无负担的远程监测,从而改变糖尿病领域。此外,通过在线和数字技术生成的数据——作者建议将其归为“digitosome”一词——通过其所代表的信息的数量和种类,构成了识别新的数字标志物和风险模式的强大潜力,最终与临床数据相结合,可以改善糖尿病管理和生活质量,并预防糖尿病相关并发症。从一个仅对少数空腹血糖和糖化血红蛋白的近期测量值进行描述的患者世界,转变为一个可以同时考虑数千个时间点的各种关键参数的患者、医疗保健专业人员和研究科学家的世界,将深刻改变糖尿病的预防、管理和患者特征的方式,以及如何在科学上进行研究。实际上,本综述探讨了糖尿病的数字化如何影响糖尿病的所有领域——预防、管理、技术和研究——以及它如何补充但不能替代传统临床环境中通常所做的工作。这种深远的转变是一个真正的变革者,应该被所有人接受,因为它可以为患者提供可转移的坚实研究结果,提高一般健康素养,并为医疗保健专业人员和糖尿病患者提供日常决策过程的便利工具。
Diabetes Metab. 2018-9-19
Rheumatol Int. 2018-4-30
Rev Med Interne. 2020-3
J Diabetes Sci Technol. 2018-11
Am J Med. 2020-4-20
Diabet Med. 2018-2-9
Int J Clin Pract Suppl. 2010-2
J Med Internet Res. 2025-8-5
J Diabetes Metab Disord. 2025-5-30
Diabetes Metab Syndr Obes. 2025-1-8